1. Home
  2. SABS

SABS

SAB Biotherapeutics Inc.

Logo SAB Biotherapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Founded: 2014 Country:
United States
United States
Employees: N/A City: SIOUX FALLS
Market Cap: 42.5M IPO Year: N/A
Target Price: $15.50 AVG Volume (30 days): 16.3K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -7.64 EPS Growth: N/A
52 Week Low/High: $4.00 - $14.50 Next Earning Date: 05-14-2024
Revenue: $2,238,991 Revenue Growth: -90.63%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: